PAREXEL Announces Enhanced Global Data Operations Offering to Drive Efficiencies for Life Science Companies
BOSTON, December 18, 2017-PAREXEL International Corporation, a leading global biopharmaceutical services provider, today introduced its enhanced Global Data Operations (GDO) solution, with augmented processes and expertise that further bolsters its world leading clinical data services, including data management, statistical programming and biostatistics.
The enhanced offering is designed to help the biopharmaceutical industry reduce time to market and R&D costs for clinical trials, including complex multi-indication trials. PAREXEL is introducing features with its GDO offering including:
- Clinical Metadata Repository: A new offering which provides clients with an extensive standards library to help simplify and automate the data collection and analysis process from protocol development through final study report. The Clinical Metadata Repository provides interoperability between the clinical data collected with different data standards and supports automated mapping into CDISC’s SDTM, and ADaM, effectively reducing mapping workload in data management; and
- Adaptive Trials Offering: A comprehensive set of innovative services and technologies for the design, data management, and logistics necessary for informed planning and execution of adaptive trials. Recognized as a promising approach to create upfront efficiencies and cost savings, clients can utilize adaptive trials to reduce uncertainty when planning, better inform decision making, and reduce risks for subjects and sponsors.
PAREXEL’s GDO services are accessible as part of the Company’s full service clinical trial management and execution or on a functional outsourcing, or Functional Service Provider (FSP), basis. PAREXEL’s FSP approach allows clients to cost-effectively expand their resources to operate in a flexible model and tailored to the unique needs of each trial. The offering is also compatible with all major Electronic Data Capture (EDC) providers.
“As sources of data have increasingly become more diverse, regulatory agencies are requesting greater standardization for submissions. Further, the FDA is encouraging the adoption of alternative trial designs, including adaptive trials, as an increasingly important aspect of the drug development journey,” said Jason Martin, Corporate Vice President, Global Data Operations, PAREXEL. “With PAREXEL’s GDO offering, we are harnessing the power of more than 2,000 global experts to respond to these evolving dynamics with end-to-end, flexible solutions that meet the evolving and diverse needs of our clients, and as a result, accelerate timelines while reducing R&D costs.”
PAREXEL’s enhanced GDO offering with the new Clinical Metadata Repository is the latest addition to PAREXEL’s Connected Journey™ of more than 40 data-driven services and is currently available worldwide. For more information on the enhanced GDO offering please visit: http://www.parexel.com/GDO.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the integrated clinical development and regulatory information management process. Headquartered near Boston, Massachusetts, PAREXEL has approximately 18,900 employees with offices in 85 locations in 52 countries around the world. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
# # #
PAREXEL Contacts:
Media:
Wendy Ryan
Tel.: +1 781-434-5104
Email: Wendy.Ryan@PAREXEL.com
Jenny Radloff, PAN Communications
Tel.: +1 617-502-4300
Email: PAREXEL@pancomm.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
